Genomic Health Inc. announced results from three studies of the Oncotype DX(R) Colon Cancer test at the 2013 Gastrointestinal (GI) Cancers Symposium, including new data demonstrating that Recurrence Score(R) (RS) results changed treatment recommendations in 45% of the enrolled stage II colon cancer patients. Presentations also include positive findings from a second health economics analysis suggesting that use of the test may result in a significant reduction in direct medical costs and improve patient well-being. Additionally, the company announced that the Journal of Clinical Oncology (JCO) has accepted for publication results from its second large clinical validation study of stage II colon cancer patients enrolled in CALGB 9581 confirming that the Oncotype DX test improves the ability to differentiate higher from lower recurrence risk beyond conventional factors.

Consortium, a prospectively designed study analyzed treatment decisions for 141 stage II, T3 MMR-proficient colon cancer patients across 17 sites demonstrating that the use of the Oncotype DX Colon Cancer test changed treatment decisions 45% of the time and led to an overall reduction in chemotherapy use. Second Health Economics Study Reconfirms Test's Cost Effectiveness: An analysis of 141 patients from 17 sites in the Mayo Clinic Cancer Research Consortium demonstrated the value of using the Oncotype DX test to identify stage II colon cancer patients with low risk of recurrence. After receiving the Recurrence Score results, physician recommendations for adjuvant chemotherapy in patients with low risk of recurrence decreased by 22%, which resulted in direct medical care costs savings of $4,200 per patient.